Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Ingrid Mayer, MD, Vanderbilt-Ingram Cancer Center Identifier:
First received: August 3, 2000
Last updated: August 10, 2012
Last verified: August 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2003
  Primary Completion Date: July 2003 (Final data collection date for primary outcome measure)